Davies Veterinary Specialists (DVS) has confirmed its programme of free CPD for vets over the next 10 months, including a special Orthopaedics Roadshow this autumn.
The evening CPD sessions will be held in the practice's purpose-built lecture theatre and will run monthly from October 2010 until July 2011. Meanwhile the roadshows will run throughout October and November, visiting four venues in London and the Home Counties north of the city.
The CPD meetings are all free of charge. They will cover a broad range of topics including anaesthesia (21st July 2011), cardiology (21st April 2011), cytology/oncology (19th May 2011), diagnostic imaging (24th March 2011), ophthalmology (23rd June 2011), orthopaedics (21st & 28th Oct, 4th & 11th Nov 2010), medicine (20th Jan 2011), neurology (25th Nov 2010) and soft tissue surgery (24th Feb 2011), presented by leading specialists from DVS. They will be held on the evening of the third Thursday of every month, with registration commencing at 7pm.
Complimentary drinks and a finger buffet are included. The evenings will close at 9pm, including time for questions and informal discussion. CPD certificates will be provided on request. For further details please contact Marion Kitchener on 01582 883950 or email marion.kitchener@vetspecialists.co.uk
The Orthopaedics Roadshow will kick off at DVS in Hertfordshire on 21 October. DVS's veterinary orthopaedics experts Richard Whitelock, David Thomson, Rob Rayward, Manuel Jiménez Peláez and Mark Morton will then take to the road to visit Aylesbury, Northampton and North London, to share knowledge on common orthopaedic conditions.
Veterinary nurses are invited to attend DVS's in-house nurses CPD programme, free of charge, by prior arrangement. Seminars are being run monthly from 20 September until 22 November 2010. A programme for 2011 will be available in the near future, for further information contact DVS Training Manager Liz Branscombe on 01582 883950 or email lbranscombe@vetspecialists.co.uk
Dr David Gould, who organises DVS's veterinary CPD, said: "The last CPD series sparked some excellent questions and discussion. With the new programme we have decided to stick to one discipline per session rather than two, to make sure we have plenty of time to accommodate as many questions and view points as possible. The orthopaedics roadshow is a new venture, motivated by a desire to make our experience of the wide variety of interesting orthopaedics cases we have received as accessible as possible to small animal practitioners."
For further details on DVS visit the website at http://www.vetspecialists.co.uk/
Mr Wilson faced two charges. The first was that in October 2017, he provided inaccurate information to an insurer in respect of a Labrador he treated by saying that the dog was presented to him with a lame left foreleg on 13 June 2017, when in fact the dog was presented for treatment on 7 June 2017 and that his conduct was therefore dishonest and misleading.
The second charge was that between 17 January 2017 and 17 January 2018 he failed to have any arrangements in place for Professional Indemnity Insurance (a requirement of the Code of Professional Conduct) and then, that between 8 January and 5 December 2019, he failed to respond to reasonable requests from the RCVS regarding his Professional Indemnity Insurance.
Prior to the hearing, Mr Wilson made an application to the Committee to adjourn the hearing subject to the Committee accepting his undertakings to remove himself from the Register and never to apply to be restored.
Mr Wilson’s legal representative at the hearing submitted to the Disciplinary Committee that granting the application would be in the public interest on the basis that Mr Wilson was 68 years of age and had now retired from the profession and closed his practice, that he had dedicated his entire working life to veterinary practice, had a previously long and unblemished career with no other complaints, and that he was well-regarded by clients and professional colleagues.
The application was not opposed by the RCVS whose representative informed the Committee that, relating to the charge of dishonesty, the College had taken into account that the insurance claim form was not submitted by Mr Wilson himself, and that there is no evidence of any financial motivation behind the charge nor any allegation of harm to an animal.
Taking into account the submissions from Mr Wilson’s representatives and from the RCVS, as well as precedent cases for such applications, the Committee decided that Mr Wilson’s voluntary undertakings went well beyond any sanction that could be imposed by the Committee and considered that the application would protect the public interest, confidence in the profession, and the welfare of animals.
Professor Alistair Barr FRCVS, chairing the Disciplinary Committee and speaking on its behalf, said: “The Committee decided that this is not a case in which the public interest or the welfare of animals demands that there be a full hearing, with determinations made by the Disciplinary Committee. Taking into account proportionality, and weighing in the balance the public interest, the interests of justice, the need to protect the welfare of animals, as well as the interests of both parties, the Committee decided to accede to the respondent’s application.”
The full findings of the Disciplinary Committee can be found at www.rcvs.org.uk/disciplinary
Jurox says the reformulation will also help reduce waste associated with unpreserved ampule formulations and will help streamline portfolios with a requirement for only one buprenorphine listing.
Dr Dan Cripwell BSc (Hons) BVSc CertAVP (EM) CertAVP PgCert (VPS) MRCVS, Advanced Veterinary Practitioner and senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution of our multidose buprenorphine formulation. We constantly strive to provide the veterinary profession with first class clinical and technical support and our ability to perform in-house product research and development is also a great strength; this allows us to remain agile enough to make adaptations in an area where not much has changed in the past few years.
“In this instance, we were able to examine what improvements could be made to our existing drug portfolio and respond to the profession’s feedback with the redevelopment of the commonly utilised opioid analgesic, buprenorphine. Our hope is that, as well as the recent mixing claims added to the product licence, this development will encourage the best clinical use of the drug and, in turn, improve patient experience and outcome.”
For more information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
Medichem International has produced an A4 sized laminated poster which illustrates the correct way to wash and disinfect hands thoroughly.
The poster has a sticky back enabling it to be placed near to hand washing facilities in the practice.
If you would like copies of the poster, they are available free of charge by emailing info@medichem.co.uk and stating your name, practice, address and postcode.
Matthew, who holds a European Certificate in Small Animal Surgery, is one of a small group of veterinary dentists in the UK. He has a special interest in the endodontic (root canal) treatment of teeth.
Ray Girotti, Hospital Director at Lumbry Park, said: "The increasing prevalence of oral and dental disease among dogs and cats and its potential to cause significant pain and infection, not just in the oral cavity but within the whole body, highlights the importance of advanced dental care.
"We are delighted to be working with Matthew. He will be accepting referrals for a range of dental problems, including fractured teeth, root canal treatment, prosthetic crowns, fractured jaws, oral tumours and orthodontics.
"In leading our dental referral service, he will work alongside our specialist teams in cardiology, internal medicine, orthopaedics, neurology, diagnostic imaging and anaesthesia to ensure that we are providing a full service and comprehensive approach to the care of our patients."
Matthew added: "I’m excited to be launching a new dental referral service at Lumbry Park. The advanced facilities it offers, including the capability to work with specialist anaesthetists and to utilise the latest in-house 3D CT and MRI imaging equipment, make it a fantastic opportunity and I’m looking forward to working closely with my colleagues to deliver an outstanding dental referral service."
The following batches are affected:
Dechra is contacting wholesale dealers and asking practices to examine inventory immediately and quarantine products subject to this recall.
For further information contact Ms Carol Morgan: carol.morgan@dechra.com .
Janssen Animal Health has launched Domosedan Gel, an oromucosal gel for the sedation of horses.
Janssen says Domosedan Gel, which contains 7.6 mg/ml (40mcg/kg) detomidine, induces sedation and analgesia with the efficacy and recovery comparable to Domosedan injection. Domosedan Gel is administered under the horse's tongue, so it is rapidly absorbed.
The company also says Domesedan Gel can replace physical restraint and improve safety during treatments, diagnostics and transport, and that the gel is ideal for horses that are nervous or needle-shy and when owners need more control during clipping, shoeing, dental treatments and boxing.
Nicki Glen, marketing manager at Janssen Animal Health said: "Domosedan Gel is proven to be both effective and easy-to-administer with 98% of horses accepting the gel and owners finding it easy and convenient to use.
"The gel starts to be absorbed immediately and demonstrates a reliable sedatory effect and high safety margin, making it an ideal solution for sedation and restraint when performing non invasive procedures on horses."
For further information, please contact your Janssen Animal Health territory manager.
There will be 20 presentations from some of the world's leading experts, covering topics such as detection and diagnosis, advances in veterinary oncology, supportive care for the cancer patients, how to build a partnership with pet owners and, of course, feeding the cancer patient.
The presentations will be streamed live and available on demand afterwards, at https://learn.hillsvet.com/en_GB/hills-global-symposium-2023
Dr. Iveta Becvarova, Senior Director of Global Academic & Professional Affairs at Hill's Pet Nutrition said: "This year’s Hill’s Global Symposium will offer the latest advancements and innovations to help veterinary professionals support and counsel their clients, and provide the best care possible to the pets in their care."
Novartis Animal Health has launched Zolvix, billed as the first truly novel anthelmintic class for livestock to be launched in more than 25 years, together with a new drenching system designed to make drenching faster, easier and more accurate.
Zolvix contains a new active ingredient, monepantel, which kills all key sheep gastro-intestinal nematodes (roundworms), including those resistant to the existing treatments.
According to the company, the development of this new drench follows the persistent challenge from worms that have developed resistance to the three other classes of drench - white (benzimidazole or 1-BZ), yellow (levamisole or 2-LV) and clear (macrocyclic lactone or 3-ML) and combinations of these. Zolvix has a unique mode of action and so forms a fourth generation of anthelmintic, which will be known as the 4- AD, or orange drench class
Novartis Animal Health has prioritised the UK and Ireland as key launch countries for Zolvix to provide their sheep farmers with an answer to the pressing challenge of increasing anthelmintic resistance.
Lesley Stubbings, an Independent sheep consultant and Sustainable Control of Parasites in Sheep (SCOPS) panel member, said: "Resistance has become an ever increasing threat since the last new anthelmintic group was introduced to the UK market more than 25 years ago. Zolvix offers farmers a valuable opportunity to maintain good worm control and prolong the effective life of the existing products. Following the SCOPS guidelines to carefully integrate Zolvix into worm control strategies, before the other groups fail, will allow our sheep industry to reap the full benefits of this new novel group."
A study carried out by Novartis in conjunction with the Hopkirk Research Institute showed that Zolvix treated sheep gained 33.5%, or 2.8 kg deadweight, more than sheep treated with a drench to which they were resistant.
Novartis Animal Health Brand Manager Simon Harris said: "Parasite resistance is a growing problem that decreases the productivity of sheep of all ages. Many veterinarians and farmers are concerned about this, with an increasing number of farmers reporting resistance to the three groups of wormers that have been available up to now, so the introduction of Zolvix is very timely."
At the same time, the company has also launched an award-winning new drenching system designed to offer 'a superior drenching experience for both animal and operator'. The new Optiline Drencher and Optivix backpack system were developed in collaboration with drenching specialists Simcro Tech Ltd.
The Optiline Drencher has already won several design and engineering awards, including a bronze award in the 2009 NZ BEST design awards, a coveted International Forum (IF) 2010 product design award from Germany and the prestigious Bayer Innovators Award for design and engineering.
It was also a finalist in the New Zealand Agritech Innovation Awards reached the finals in three categories of the 2009 New Zealand Trade and Enterprise International Business Awards.
The Optiline drencher is coupled with a durable, light Optivix backpack that has been specially tailored to provide left or right-handed operators with the same wide range of adjustment. It also has two drench cradles - at chest and hip level - to ensure maximum comfort.
Mr Harris said: "This drencher is best appreciated during use. Contact your local Novartis Animal health representative to arrange a trial."
Dr Mostert admitted to his conviction but denied that it rendered him unfit to practise as a veterinary surgeon.
He also admitted not disclosing his conviction to the RCVS but denied that it amounted to dishonesty or was misleading and that failing to do so amounted to disgraceful conduct in a professional respect.
The Committee first considered whether Dr Mostert’s conviction affected the public interest, which included the need to maintain public confidence in the profession by upholding proper standards of conduct and behaviour for members of the profession.
The Committee noted that the conviction involved dishonesty relating to false statements about the value of goods sent to the USA.
The Committee felt that a conviction for a serious offence involving dishonesty would have a negative impact on public confidence in the profession, and that its reputation would be damaged if proper standards of conduct and behaviour were not upheld.
The Committee also noted that as the products that Dr Mostert imported into the USA were not labelled as coming from a foreign market and were not labelled as needing to be administered by a vet, his conviction also related to animal safety, as anyone who accessed the medications could believe that it was safe for them to be given to an animal.
The Committee then considered Dr Mostert’s failure to declare the conviction to the College on three separate occasions.
Dr Mostert testified that, at the time, he did not believe he had to disclose his conviction as it occurred in a country where he had not practised as a veterinary surgeon.
He also said he had not taken the time to read and interpret the application form accurately.
However, the Committee considered that the wording around convictions on the application and annual renewal forms is very clear and that, as a veterinary surgeon, Dr Mostert would be familiar with such documents.
The Committee considered that it was inconceivable that an experienced veterinary surgeon, making a declaration of this kind to his regulator, would not have understood that a serious conviction in the USA, dating from June 2017, was a conviction that he was obliged to disclose.
The Committee therefore found Dr Mostert’s failures to declare his conviction dishonest.
Judith Way, Chairing the Committee and speaking on its behalf, noted that in deciding upon the appropriate sanction, the case did not involve any actual harm to an animal or human and that Dr Mostert had had a long and otherwise unblemished career.
However, a key aggravating factor was that the action that led to the conviction resulted in financial gain through the creation of a business enterprise and that Dr Mostert falsely declared the value of goods.
The extent of any financial gain was not known to the Committee, but the business operated on the basis that false declarations were repeatedly made.
Judith said: “After careful consideration the Committee has concluded that in all the circumstances, a lengthy period of suspension would properly reflect the gravity of the case and satisfy the public interest. The Committee has decided that the appropriate length of suspension is one of 18 months.”
The Committee’s full findings can be viewed at www.rcvs.org.uk/disciplinary
Speakers include Prof. Jo Dukes McEwan, Head of Service, Professor in Small Animal Cardiology (University of Liverpool), Doctor Jennifer Schissler, Veterinary Dermatologist, Best Friends Animal Hospital & Urgent Care Unit (US), and Doctor Pascal Prélaud, Dermatologist, CEO ADVETIA Vet Hospital Center (France).
Participants will also be able to access to an immersive experience, the Vet Symposium Village, which includes the Live Stage, Vet Lab, Clinic Lounge, and Innovation Hub, all offering exclusive videos and lectures.
The event will be translated into Chinese, French, Spanish, Italian, Portuguese, Russian, and German, and a replay of the event will be available until the end of the year.
Dr. Jennifer Welser, Chief Medical Officer, Mars Veterinary Health, said: “It’s more critical than ever for pet professionals from various countries, fields, and perspectives to meet and share their knowledge.
"I look forward to participating in the Vet Symposium and speaking with my peers on topics ranging from mental health to advancements in quality medical care and retaining veterinary talent.”
https://digital-vetsymposium2022.com/
The new products are:
Leon Wright, Managing Director, said: "At Vet Direct, we’re always looking for ways to improve our service – making small changes which will have a big impact on the levels of care our clients can provide.
"We know that vets, veterinary nurses and practice managers don’t always have the time to try out new products before purchasing, and that’s why our dedicated team of sales staff test every item before adding them to our catalogue - ensuring that we only stock the highest quality products."
For more information on any of the new products, visit www.vet-direct.com or call 0800 068 3300.
Ceva Animal Health has extended its Meloxidyl dogs and cats’ range with the launch of a new 5ml Meloxidyl oral suspension for cats.
The company says the new bottle size will provide more prescription options for veterinary practices currently stocking 15ml bottles and is a perfect post-surgery size to send patients home with. The bottles are also clear brown in colour; designed to make it easier for cat owners to see how much liquid is left in each bottle.
Meloxidyl oral suspension for cats contains meloxicam for the alleviation of pain and inflammation. It is licensed for the treatment of musculo-skeletal disorders and the alleviation of post-operative pain.
Rob McLintock, business unit manager at Ceva Animal Health said: "The new 5ml Meloxidyl oral suspension for cats’ bottle will provide veterinary practices with more prescription options for the management and alleviation of pain and inflammation in cats."
To support the launch of the new 5ml Meloxidyl presentation, Ceva is running a competition to win one of five BSAVA Manuals of Anaesthesia and Analgesia by answering one question: ‘How many millilitres are in the new Meloxidyl cat bottle’?
To enter the competition, email analgesics-group@ceva.com. Include ‘Meloxidyl competition’ in the subject line and contact details and the answer to the question in the main body of the email.
For further information on Ceva’s analgesic product range, contact your local Ceva territory manager, email analgesics-group@ceva.com or call 01494 781510.
The lecture, which will take place at 4:30pm on Friday 6th April in the Premier Lounge, Arena Birmingham, is presented by Dr Ivan Crotaz BVetMed MRCVS and human anaesthesiologist Dr Muhammed Nasir MBBS BSc FFARCSI MRCA (pictured right).
Chris Geddes MRCVS, Marketing Manager for Docsinnovent, says the lecture is not to be missed for two reasons: "Firstly, the topic is very current – a lot of new information is emerging about regurgitation and reflux in our veterinary patients. We are learning that the starving times we have all been recommending for years may not be ideal after all.
"Secondly, the lecture will be presented by both a vet with an interest in airway management (Dr Crotaz) and a renowned human anaesthesiologist (Dr Nasir) – so we as a profession can learn from what is happening in the field of human medicine."
The session will include a review of the situation in human anaesthesia. The anatomy of the upper airway and oesophagus of the major small animal veterinary species will be examined as well as the pathogenesis, occurrence and disease associated with reflux.
Pre-, intra- and post-operative management will be discussed, as well as current recommendations for starving veterinary patients.
The lecture is free for BSAVA attendees to attend and will be followed by drinks and nibbles supplied by Docsinnovent, who are also exhibiting at BSAVA congress on stand 1006.
The petition follows the news that IVC is to launch its own telemedicine service, joining three others already in the game, at least one of which is pushing for a relaxation of the rules surrounding the prescription of POM-V medicines.
For clarity, veterinary surgeons are currently allowed to remote prescribe medicines for animals that meet the definition of 'under his care' (i.e. seen immediately before, or "recently enough or often enough for the veterinary surgeon to have personal knowledge of the condition of the animal or current health status of the herd or flock to make a diagnosis and prescribe").
In other words, there is nothing to stop bricks and mortar practices offering video consultations and prescribing medicines to those of their existing clients that they have seen recently enough.
What Shams and the BVU are petitioning against is the idea of allowing companies staffed by veterinary surgeons to prescribe veterinary medicines for animals that they have never seen in the flesh.
They argue that remote prescribing will:
First and foremost risk animal patient welfare and herd health
Create a two-tier system of care within the profession
Break down the practice-based vet-client relationship
Disrupt veterinary services due to complications related to out-of-hours emergency cover, transfer of patient and patient histories etc. of remotely treated patients
Cause clients to face increased costs by paying for telemedicine consultations and then requiring examination and treatment in practice
Negatively impact the financial condition of veterinary practices and professionals.
These all seem very possible consequences of allowing remote prescribing, indeed some have already come to pass in the world of human medicine following the launch of Babylon.
The counter argument is that remote prescription will improve access to veterinary care as people don’t have to flog down to the practice for a flea treatment and the cost of a consultation is reduced. There is surely truth in that.
The other point that is fundamental to this debate is the type of drug being prescribed remotely. With so many small animal parasiticides having already gone OTC, is it really necessary to talk to a veterinary surgeon before buying a POM-V flea treatment? Perhaps not.
However, that doesn’t necessarily present a case for remote prescribing such drugs; if they don’t need veterinary input, then you could equally argue they just need reclassifying.
So, should you sign this petition? Well, I think so, yes. Remote prescribing will come. It’s inevitable. But given the risks, surely the pragmatic starting point is to trial remote prescribing amongst existing clients of bricks and mortar practices, and only if that is successful to broaden it to non-clients of bricks and mortar practices.
If both those proved successful, and with technology advancing in the background, it might then be sensible to look at whether non bricks and mortar practices could remote prescribe. But that’s quite a big ‘might’.
Meantime, you can sign the petition here: https://www.change.org/p/royal-college-of-veterinary-surgeons-stop-authorising-prescription-of-pom-v-without-physical-examination-of-the-patient
You can discuss the petition with Shams here: https://www.vetsurgeon.org/nonclinical/f/6/t/28273.aspx
The company says its new design is modular, allowing veterinary practices to customise kennels to their requirements now, and then upgrade them and add components as their needs change over time.
Options include dimmable daylight lighting or Casco Pet’s DRC Lighting System with three modes: Daylight (white), Recovery (red), and Cleaning (blue UVA), built-in thermostatically controlled heat mats, an illuminated glass whiteboard for easy recording and viewing of patient notes, integrated IV stand and pump holders, an internal ceiling vent and ventilation kit and an integrated plug socket and USB port .
Matthew Bubear, CEO, Casco Pet, said: “Our new generation of WellKennels, which have been designed to meet the dynamic demands of modern veterinary practices, allow practitioners to elevate the care they provide today while ensuring sustained adaptability for the needs of tomorrow."
WellKennels are certified by the International Society of Feline Medicine and are part of FearFree’s Preferred Product Program, the global initiative dedicated to preventing and alleviating fear, anxiety and stress in pets.
The new WellKennels will be unveiled at the London Vet Show, ExCel London, 16-17 November, on Stand H35.
https://cascopet.com/uk/products-and-services/veterinary
The toolkit is part of a major study, the ‘Old Age Pets (OAP) research project’, recently funded by BSAVA PetSavers at the University of Liverpool.
The ACT includes an owner checklist for home triage and a leaflet which explains the more common health problems affecting aged dogs.
There's a practice waiting room poster which includes a QR code to give clients access to a digital version of the leaflet.
The leaflet recommends working through the checklist at least every six months and keeping completed versions for comparison, to monitor dogs as they age.
PetSavers says that some clients may benefit from advice and guidance from RVNs or PCAs on how to complete the checklist for the first time.
BSAVA has also curated a collection of articles, podcasts, lectures and book chapters to support veterinary professionals in caring for senior dogs: http://www.bsavalibrary.com/petsaversact.
Professor Carri Westgarth from the University of Liverpool said: “We conducted this research project kindly funded by BSAVA PetSavers in order to help owners and veterinary professionals provide great care for our loved pets as they age.
“Our investigations uncovered common physical and behavioural signs in dogs that owners observe and for which support from the veterinary practice would be beneficial.
"Our simple evidence-based checklist is designed to engage owners and importantly stimulate efficient discussion with their veterinary team.”
Free digital copies of the leaflet and poster can be downloaded here: http://www.bsavalibrary.com/content/cilgrouppetsaversact, where veterinary professionals can also request free printed copies for their practices.
https://www.bsava.com/petsavers/our-impact/citizen-science-project.
Micro-nutrition specialist Agrimin has launched All-Trace Biotin Gold, the seventh bolus in the company's All-Trace range.
The new bolus is the result of extensive in-house research and development which aimed to formulate a cost-effective, micro-nutrition bolus suitable for dry cows and heifers at risk from lameness, which affects up to 20 per cent of the UK national herd. According to Agrimin, the relationship between Biotin and its benefits on ruminant hoof health is receiving increasing attention. The company says it is the first micro-nutrition specialist to directly address this livestock health issue by using a bolus.
The Biotin Gold bolus for dairy cows and heifers delivers the target level of 20 mg per head, per day of Biotin over 120 days. In addition, the bolus also delivers the full, daily requirement of copper, cobalt, selenium and iodine as well as levels of zinc, manganese and vitamins A, D3 and E.
Administration is simple and convenient during the drying off period as many livestock are already going through a crush to have their feet trimmed and undergo other healthcare routines such as intramammary treatments.
For dry cows, two boluses are given to each cow at the point of drying off. They lie in the rumen/reticulum and slowly dissolve from a constant surface area providing a continuous and regular supply of trace elements and vitamins to the animal. The boluses dissolve completely and leave no residue in the rumen.
Agrimin says heifers respond very well to Biotin supplementation and studies have shown that supplying Biotin in the later stages of pregnancy produces the most effective results. This late stage of pregnancy is also the critical period for the transfer of vital nutrients from mother to calf and so the trace element content of All-Trace Biotin Gold will benefit both animals. Two boluses are given to each heifer at around three months pre-calving.
All-Trace Biotin Gold is available in packs of 20 boluses, which will supplement 10 cows or heifers at a cost of around £9.50 per animal for two boluses. For more information about bolus technologies and micro-nutrition, please visit www.agrimin.com or call 01652 688046.
Christine said: "Tests conducted by the Animal and Plant Health Agency have confirmed that the virus responsible for COVID-19 has been detected in a pet cat in England.
"This is a very rare event with infected animals detected to date only showing mild clinical signs and recovering within in a few days.
"There is no evidence to suggest that pets directly transmit the virus to humans. We will continue to monitor this situation closely and will update our guidance to pet owners should the situation change."
Yvonne Doyle, Medical Director at Public Health England, said: "This is the first case of a domestic cat testing positive for COVID-19 in the UK but should not be a cause for alarm.
"The investigation into this case suggest that the infection was spread from humans to animal, and not the other way round. At this time, there is no evidence that pets can transmit the disease to humans.
The pet cat was initially diagnosed by a vet with feline herpes virus, but the sample was also tested for SARS-CoV-2 as part of a research programme at the Centre for Virus Research at Glasgow University. Follow-up samples tested at the APHA laboratory in Weybridge confirmed the cat was also co-infected with SARS-CoV2 , the virus known to cause COVID-19 in humans.
BSAVA advice for practising vets about coronavirus is here and further information about testing is available here.
Dr Sabela Atencia DVM MVM Dip-ECVIM CA MRCVS is an internal medicine specialist who holds the European Diploma in Small Animal Internal Medicine.
During her research for her Masters degree on muscular dystrophy in the Japanese Spitz breed, she contributed to knowledge of the underlying mutation of the disease, facilitating the development of a genetic test.
Sabela enjoys all aspects of canine and feline Internal Medicine, but is particularly interested in endoscopy, endocrinology and genetics.
Dr Owen Davies MA VetMB MVetMed MANZCVS(SAM) MRCVS, a veterinary medical oncology clinician, holds a Masters degree based on research into canine lymphoma.
Owen is interested in all aspects of medical oncology, especially haematopoietic malignancies, targeted therapy for cancer and paraneoplastic disease. He has recently completed a residency in veterinary oncology at the Royal Veterinary College and has just passed the DACVIM examinations in Oncology.
Dr Elisabetta Mancinelli DVM CertZooMed Dipl ECZM (Small Mammal) MRCVS is a European Veterinary Specialist in Zoological Medicine (Small Mammal Medicine and Surgery) and an RCVS Recognised Specialist in Zoo and Wildlife Medicine.
She was the first veterinary surgeon to undertake the European College of Zoological Medicine (ECZM) Residency in Small Mammal Medicine, which she completed at The Royal (Dick) School of Veterinary Studies, Edinburgh.
Elisabetta will lead and further expand the established exotic pet service at the Hospital.
Acting Hospital Director, Professor Stuart Carmichael said: "As we continue to extend the range of services and expertise we offer to our clients, we are delighted to welcome these three distinguished professionals to the team here at Highcroft. They will make a great contribution and it’s great to have them aboard."
Highcroft Veterinary Referrals is based at 615 Wells Road, Whitchurch, Bristol and can be contacted on 01275 832410.
Photo: Left to right: Dr Elisabetta Mancinelli, Dr Owen Davies, Dr Sabela Atencia
Saliva was collected from 237 horses at the UK welfare charity, Bransby Horses, where EquiSal Tapeworm saliva testing was used to inform on anthelmintic administration over the course of a year. This diagnostic-led approach reduced the use of anti-tapeworm treatments by 86% compared to 6 monthly interval treatment strategies.
Austin Davis Biologics Ltd, the maker of the EquiSal Tapeworm saliva test, says it accurately diagnoses horses with a tapeworm infection, providing a low, borderline or moderate/high diagnosis.
Treatment is recommended for horses with a borderline or moderate/high result2.
In this latest study, the company says most horses diagnosed below the treatment threshold in the first saliva test remained below the threshold in the following two tests and 168 horses (71%) required no anti-tapeworm treatment at all.
Importantly, no increase in tapeworm infection prevalence was observed during the study period and only seven horses received treatment following all three saliva tests, suggesting that some horses are more susceptible to tapeworm infections.
The EVJ has prepared a podcast summarising the study findings here: https://evj.podbean.com/e/evj-of-the-hoof-podcast-no-1-march-2018-use-of-saliva-based-diagnostic-test-to-identify-tapeworm-infection-in-horses-in-the-uk/.
The study authors have also prepared a video abstract which can be viewed at https://vimeo.com/254338616 .
EquiSal saliva collection kits are available at trade prices to veterinary practices and SQPs. Contact enquiries@equisal.com or visit www.equisal.com for more information.
References
The clinic will assess cats and dogs under six months old where a heart murmur has been detected.
Willows will then recommend a course of action and, if required, carry out keyhole surgery.
Chris Linney, head of cardiology at Willows, said: "This is the first specialist-led, congenital heart disease clinic in the country and will use some of the latest and most advanced equipment available in the veterinary world. As well as advanced ultrasound, we also have state-of-the-art CT available for assessment of complex cases.
"With the support of the 24/7 hospital service and other specialist disciplines here at Willows, it means we can offer excellent care to our patients, their owners and referring vets.
"All young animals with murmurs may benefit from the clinic, but those that are always recommended to undergo assessment are puppies with murmurs grade three (out of six) and over, and kittens with murmurs grade four (out of six) and over.
"By reviewing these animals at a younger age, we hope to be able to put care plans in place that can improve their long-term health.
"We will also offer a precise diagnosis, outlook and prognosis on the cause of the heart murmur and, where needed, carry out minimally-invasive keyhole surgery.
"Often, the earlier these are performed the better the outlook for the patient."
For more information, visit www.willows.uk.net.
Jonathan Hill (UK Country Manager) said: “I’m delighted to announce that TVM UK is changing its name to Dômes Pharma.
"This will align with the other operating companies within the group.
"TVM UK has always been owned by the Dômes Pharma group, and since the start of our journey in the UK market we have been synonymous with expertise and outstanding levels of customer service in selected speciality segments of the animal health market and this won’t change.”
“Under the Dômes Pharma name we will continue to build and grow on this very strong foundation.
"I’m looking forward to working with the entire Dômes Pharma team as we increase our presence as a leading specialty pharmaceutical company, bringing our ethos to new speciality segments with innovative products and solutions for vets in the UK.
"Dômes Pharma remains a family-owned business, and the culture of the company really reflects this and we live by our values of kindness, boldness and responsibility.” https://www.domespharma.com https://www.tvm-uk.com
MSD Animal Health has launched Zuprevo Cattle, which contains a novel antibiotic molecule to help combat bovine respiratory disease (BRD).
Zuprevo Cattle contains the active ingredient tildipirosin (180mg/ml), a new 16-membered, tribasic macrolide unique to animal health. It is licensed for the treatment and prevention of BRD associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
According to MSD Animal Health livestock veterinary adviser Paul Williams MRCVS, the new product works extremely quickly in the animal, as well as offering the longest duration of activity in the lungs of all the macrolide antibiotics currently on the market. He says it is also extremely convenient to use: "Zuprevo is readily absorbed by the animal, reaching peak plasma concentrations within 23 minutes of injection. Zuprevo is readily distributed around the body and reaches lung concentration well above MIC90 for all of the three BRD target pathogens within four hours of administration. In addition, it maintains lung concentration above the MIC90 for up to 28 days, which will appeal to many practitioners."
Paul says that it is Zuprevo's 16-membered, tribasic macrolide structure that allows it to deliver these significant pharmacological benefits for the management of BRD in cattle: "Zuprevo works by diffusing into the bacterial cell where its binding action inhibits protein synthesis of the bacterial ribosome. Its unique 16-membered, tribasic structure enables enhanced penetration of the bacterial cell wall, as well as having the ability to bypass some potential bacterial resistance mechanisms."
Paul says Zuprevo also offers vets and their farmer clients important practical usage advantages: "Zuprevo is an easily syringeable solution for injection available in convenient 20ml, 50ml and 100ml vial sizes to suit different usage requirements. At a dose rate of 1ml/45kg, it offers the lowest macrolide dose volume per kg of bodyweight. At 47 days, Zuprevo also has the shortest macrolide meat withdrawal period."
Further information on this new macrolide antibiotic is available from the MSD Animal Health territory managers or by calling the company's Veterinary Services Group on 01908 685685.
The new law, which replaces the Data Protection Directive, come into effect from 25th May 2018. All businesses will be affected, including the veterinary profession, and failure to comply could result in heavy financial penalties. It is important, therefore, that all practices start to prepare for them and ensure that they will be compliant when the new legislation comes into play next year.
Renay Rickard, president of the VPMA said: "These new regulations concern how we will manage personal data, both that of our clients and our staff, and it’s imperative that we understand them and act on them. We arranged this webinar to inform our members, and were very lucky to have such a tailored presentation directly from the regulator – helped by the fact that Helen, the speaker, comes from a veterinary practice background. It was so useful, we felt that the wider veterinary community would benefit from listening to it, so we’re pleased to open it up to non-members."
The webinar content guides listeners through the key changes ahead and the steps that practices will need to take to ensure they are compliant with the new legal requirements. This includes the impact the changes will have on marketing strategies and practice positioning on sending client reminders (e.g. vaccination, appointment); sharing case histories; passing on data regarding 'bad-debtors', as well as how to approach 'tagging' clients records (for example, re debt) in compliance with the GDPR.
The webinar also provides useful information on where to turn if practices need help and advice, as well as what to do if a data breach is detected. Finally, a detailed questions and answers session covers the day-to-day scenarios in practice that involve handling or sharing client data.
The recording can be accessed on request by emailing the VPMA Secretariat, secretariat@vpma.co.uk.
Photo: GDPR - General Data Protection Regulation. data 25 may 2018. Map EU and flag. Shutterstock/a_Jarm